Andy Plump, Takeda R&D chief (Jeff Rumans for Endpoints News)

In its largest sin­gle-as­set pur­chase ever, Take­da snaps up TYK2 drug for $4B up­front

Take­da is buy­ing Nim­bus’ late-stage TYK2 in­hibitor, an oral drug for au­toim­mune dis­eases, for $4 bil­lion in cash up­front. That sets Take­da up to com­pete …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.